Action of poly-[(trans-l,2-diaminocyclohexane)platinum]-carboxyamylose (poly-plat) and cisplatin (CDDP) on the immune system was studied using isolated peritoneal macrophages and compared with liver resident macrophages from normal, CDDP and poly-plat [10 mg/kg] 
Introduction
Cisplatin (cis-diaminedichloroplatinum II) (CDDP) is a broad spectrum antineoplastic agent currently used to treat a variety of cancers (1). it has been demostrated to inhibit DNA replication (2) It has also been shown to and transcription through intrastrand and interstrand crosslinking inhibit cytokinesis in cases where the DNA has already replicated through the depolymerization of actin-like microfilaments. Cisplatin has also been shown to enhance specific cellular immune responses in tumor bearing mice (3), through activation of murine peritoneal macrophages (4, 5) .
Such activated macrophages in culture have been found to destroy tumor cells through the production of various cvtolytic factors like interleukin-lo (IL-lo0, tumor necrosis factor-o (TNF-00 (5) and nitric oxide (NO) However, it suffers from dose limiting side effects ranging from vomiting, diarrhea, neurotoxicity, nephrotoxicity, and embryotoxicity. These toxicities can be ameliorated through the hydration of patients, by the use of compounds rich in thiols, or the administration of vitamin D New compounds with differeing ligand are being synthesized in order to increase the efficacy and reduce the toxicities due to cisplatin. Lysosomal studies: Based on fluorescence measurements after acridine orange labeling, we observed a 500-fold increase in the number of lysosomes in the macrophages after only 2 h of poly-plat treatment compared to untreated macrophages. The lysosomes were plentiful in the cytoplasm of the macrophages and in the drug-induced cytoplasmic extensions radiating from the cell body. Comparatively, cisplatin treatment demonstrated only a 50-fold increase in the lysosomes, both in the cell body and the cytoplasmic extensions. Poly-plat demonstrated very little TNF-o activity, barely reaching 200 pg/ml at 24 h post-treatment.
Platinum Coordination Complexes
Cisplatin demonstrated the usual enhanced release of TNF-o at various time intervals, reaching a peak value at 2 h post-treatment (3000 pg/ml).
Compared to cisplatin treatments there was an increase in IL-lo levels in the supernatants of macrophages treated with poly-plat for up to 24 h of testing. The greatest increases were seen 2 h post-treatment (400-500 pg/ml) with a subsequent decrease from there on (Fig. 1) . IL-lo levels demonstrated a consistent increase after cisplatin treatment, reaching a maximum after 24 h. ILlo levels after poly-plat treatment demonstrated a decline after a peak at 2 h post-treatment but these levels were still equal to or above those after cisplatin treatment, However, macrophages isolated from 'poly-plat' treated mice demonstrated a significantly higher level of IL-lo (500pg/ml) than cisplatin treatment (250 pg/ml), but only after 12.days of the treatment (Fig. 2) An increased understanding of the mechanisms controlling macrophage size and number can lead to more effective treatment of distress. These results show that poly-plat is more effective than cisplatin in macrophage activation, with less toxic side effects compared to cisplatin. Further research is needed to determine the active state of poly-plat, and its relation to hepatocellular esterase concentration, as well cytokine production.
